

Anti-Potassium Channel $K_{Ca}2.3$ (C-term)

(Small-conductance Ca^{2+} -activated Potassium Channel 3; SK3; SKCa3; KCNN3)
developed in rabbit, affinity isolated antibody

Catalog Number **P4747**

Product Description

Anti-Potassium Channel $K_{Ca}2.3$ (C-term) was developed in rabbit using a synthetic peptide (C)KQIGSLESKLEHLTAS corresponding to amino acid residues 659–674 of human $K_{Ca}2.3$ as the immunogen. This sequence has 100% homology with mouse, pig, and rat. The antibody was affinity isolated on immobilized immunogen.

Anti-Potassium Channel $K_{Ca}2.3$ (C-term) recognizes $K_{Ca}2.3$ in a Western blot with rat brain membranes.

The action of potassium (K^+) channels is regulated by voltage, calcium, and a variety of neurotransmitters. Each subfamily generally consists of a primary pore forming α subunit that is associated with several regulatory subunits.¹ To date, some 70 different genes that encode the α subunits of K^+ channels have been identified. Recently, the crystal structure of the K^+ channels has been identified.²

The vast family of K^+ channels has been subdivided into the three main subfamilies: the 2 TM, 4 TM, and 6 TM K^+ channels.³ The 6 TM family of K^+ channels includes the voltage-gated K^+ (K_v) channels, the KCNQ, the EAG, the calcium-activated K^+ (Slo) subfamily (which is actually a 7 TM not a 6 TM type of channel), and the calcium-activated SK subfamily.

Structurally, the calcium-activated K^+ channels can be divided into two groups: the small or intermediate conductance potassium channels (SK/IK), and the high conductance potassium channels (BK). BK channels are expressed in virtually all cell types where they cause hyperpolarization and help to connect between intracellular Ca^{2+} signaling pathways and membrane excitability. $K_{Ca}1.1$ channels have a crucial role in smooth muscle contractility, neuronal spike shaping, and neurotransmitter release.^{4,5}

Small or intermediate conductance calcium-activated K^+ channels (SK/IK) are responsible for the slow after-hyperpolarization following an action potential. These channels are distinguished from BK channels by their high sensitivity to intracellular calcium, low conductivity, and weak or negligible voltage-dependence.⁶ Recently, four SK channels (SK1-4) have been cloned.⁷⁻⁹ SK1 and SK2 channels have highest densities in subregions of the hippocampus and neocortex, while SK3 channels are distributed more diffusely in these brain regions and predominantly expressed in phylogenetically older brain regions.¹⁰ The SK3 channels appear to be implicated in the regulation of electrical excitability and neurotransmitter release of monoaminergic neurons and have been implicated in schizophrenia, ataxia, and anorexia nervosa.¹¹ The SK4 (also called $IK_{Ca}1$) channels possess intermediate conductivity and are expressed in many tissue types including red blood cells and T lymphocytes.¹²

Reagent

The antibody is supplied as lyophilized powder from phosphate buffered saline containing 1% bovine serum albumin and 0.05% sodium azide as preservative.

Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

Preparation Instructions

Reconstitute the lyophilized vial with either 0.05 ml or 0.2 ml deionized water, depending on the package size. Further dilutions should be made using a carrier protein such as BSA (1%).

Product Information

sigma-aldrich.com

3050 Spruce Street, Saint Louis, MO 63103 USA

Tel: (800) 521-8956 (314) 771-5765 Fax: (800) 325-5052 (314) 771-5757

email: techservice@sial.com sigma-aldrich.com

Storage/Stability

Store at -20°C . For extended storage, freeze in working aliquots. Avoid repeated freezing and thawing. Storage in "frost-free" freezers is not recommended. Centrifuge before use. Working dilution samples should be discarded if not used within 12 hours.

Product Profile

The recommended working dilution is 1:200 for immunoblotting.

Note: In order to obtain best results in different techniques and preparations we recommend determining optimal working concentration by titration test.

References

1. Alexander, S.P., et al., Br. J. Pharmacol., **141**, Suppl 1:S1-S126 (2004).
2. MacKinnon, R., FEBS Letters, **555**, 62-65 (2003).
3. Gutman, G.A., et al., Pharmacol. Rev., **55**, 583-586 (2003).
4. Knaus, H.G., et al., J. Neurosci., **16**, 955-963 (1996).
5. Heppner, T.J., et al., Am. J. Physiol., **273**, C110-C117 (1997).
6. Vergara, C., et al., Curr. Opin. Neurobiol., **8**, 321-329 (1998).
7. Chandy, K.G., et al., Mol. Psychiatry, **3**, 32-37 (1998).
8. Joiner, W.J., et al., Proc. Natl. Acad. Sci. USA, **94**, 11013-11018 (1997).
9. Kohler, M., et al., *Science*, **273**, 1709-1714 (1996).
10. Sailer C.A., et al., J. Neurosci., **22**, 9698-9707 (2002).
11. Tomita, H., et al., Mol. Psychiatry, **8**, 524-535 (2003).
12. Khanna, R., et al., J. Biol. Chem., **274**, 14838-14849 (1999).

AH,MTC,PHC,MAM,TT,SM,PCG 04/20-1

Sigma brand products are sold through Sigma-Aldrich, Inc.

Sigma-Aldrich, Inc. warrants that its products conform to the information contained in this and other Sigma-Aldrich publications. Purchaser must determine the suitability of the product(s) for their particular use. Additional terms and conditions may apply. Please see reverse side of the invoice or packing slip.

SIGMA-ALDRICH™